Aardvark Director Roy D. Baynes Receives 44,964-Share Award

What Happened

• Roy D. Baynes, a director of Aardvark Therapeutics, received a grant/award of 44,964 derivative shares on 2026-08-14. The reported acquisition price is $0.00 per share (total cash paid $0). This filing reports a grant (code A), not a purchase or sale.

Key Details

• Transaction date: 2026-08-14
• Filing date: 2026-08-21 (Form 4 filed 7 days after the transaction; Form 4s are normally due within two business days, so this appears late)
• Security: derivative equity award — 44,964 shares (reported as derivative)
• Price: $0.00 per share; total reported cash = $0
• Vesting (footnote F1): vests in full on the earlier of (i) August 14, 2027, or (ii) immediately prior to Aardvark’s next Annual Meeting of Stockholders following the grant date, subject to continuous service
• Shares owned following the transaction: not specified in the filing
• Transaction code: A (award/grant)

Context

• This was an equity grant to a director (compensation), not a market buy or sale. Derivative awards can be stock options, restricted stock units (RSUs) or similar equity-based compensation; the filing shows no exercise or sale and no immediate cash exchanged. Director awards are routine forms of compensation and do not by themselves indicate insider buying or selling intent.